Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388638 | 1.00 | CYP3A4 (0.61) | CYP3A4NR4A2CREBBPPBRM1ALDH1A1 | |
| SCHEMBL9615418 | 0.90 | CYP3A4 (0.56) | CYP3A4NR4A2CREBBPPBRM1ALDH1A1 | |
| SCHEMBL8924341 | 0.81 | ALDH1A1 (0.54) | NR4A2CREBBPPBRM1ALDH1A1TSHR | |
| SCHEMBL730525 | 0.80 | NR4A2 (0.69) | NR4A2CREBBPPBRM1ALDH1A1TSHR | |
| SCHEMBL17386427 | 0.79 | CYP3A4 (0.76) | CYP3A4ALDH1A1TSHRHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL30718988 | 0.79 | NR4A2 (0.67) | NR4A2CREBBPPBRM1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL28308377 | 0.79 | NR4A2 (0.67) | NR4A2CREBBPPBRM1ALDH1A1TSHR | |
| SCHEMBL8157174 | 0.78 | GPR84 (0.65) | NR4A2CREBBPPBRM1ALDH1A1RAB9A | |
| SCHEMBL5805847 | 0.78 | NR4A2 (0.65) | NR4A2CREBBPPBRM1ALDH1A1TSHR | |
| SCHEMBL3264030 | 0.78 | NR4A2 (0.61) | NR4A2CREBBPPBRM1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143680-B | Indolines compound pyrrolidone indoline compound and preparation thereof | 深圳湾实验室 | 2024-08-30 | — | — | CN | claimed |
| CN-116143680-A | Indoline compound, pyrrolidone indoline compound and preparation thereof | 深圳湾实验室 | 2023-05-23 | — | — | CN | claimed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | claimed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | claimed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | claimed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | claimed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | claimed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | claimed |
| CN-116143680-B | Indolines compound pyrrolidone indoline compound and preparation thereof | 深圳湾实验室 | 2024-08-30 | — | — | CN | disclosed |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116143680-A | Indoline compound, pyrrolidone indoline compound and preparation thereof | 深圳湾实验室 | 2023-05-23 | — | — | CN | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2010008727-A1 | ASYMMETRIC SYNTHESIS OF ALLYL OR ALLENE OXINDOLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-01-21 | — | — | WO | disclosed |
| US-5219859-A | Chloesterol acyltransferase inhibitors; antilipemic agents; antidiabetic agents; atherosclerosis | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | CYP3A4 572/4885NR4A2 3167/4885CREBBP 1595/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | CYP3A4 572/4885NR4A2 3167/4885CREBBP 1595/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | CYP3A4 572/4885NR4A2 3167/4885CREBBP 1595/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | CYP3A4 480/4885NR4A2 3742/4885CREBBP 1873/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | CYP3A4 572/4885NR4A2 3167/4885CREBBP 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.